Table 2.
Characteristics at time of AKI diagnosis in septic patients with and without AKI progression
| Characteristics | Overall (n = 149) | Progression (n = 63) | Non-Progression (n = 86) | P |
|---|---|---|---|---|
| AKI Severity | ||||
| SCr at AKI diagnosis, mg/dL | 1.6 ± 0.5 | 1.7 ± 0.5 | 1.5 ± 0.5 | 0.022 |
| Peak SCr, mg/dL | 1.8 ± 0.8 | 2.2 ± 0.9 | 1.6 ± 0.5 | < 0.001 |
| Change in SCr a, mg/dL | 1.0 ± 0.6 | 1.3 ± 0.7 | 0.7 ± 0.4 | < 0.001 |
| SCys-C at AKI diagnosis, mg/L | 1.5 ± 0.7 | 1.7 ± 0.7 | 1.3 ± 0.7 | 0.004 |
| AKI stage 1, n (%) | 123 (82.6) | 53 (84.1) | 70 (81.4) | 0.664 |
| AKI stage 2, n (%) | 26 (17.4) | 10 (15.9) | 16 (18.6) | 0.664 |
| AKI duration, d | 2.0 (1.0-4.0) | 3.5 (2.0-5.0) | 1.0 (1.0-3.0) | < 0.001 |
| Biomarkers at time of AKI diagnosis | ||||
| u[TIMP-2]*[IGFBP7], (μg/g Cr)2 | 1169.7 (426.6-3079.8) | 2168.5 (1068.8-5274.9) | 583.2 (293.6-1666.4) | < 0.001 |
| uKIM-1, μg/g Cr | 3.1 (1.5-6.0) | 5.0 (2.7-7.3) | 2.1 (0.8-4.8) | < 0.001 |
| uIL-18, ng/g Cr | 196.5 (79.5-664.5) | 384.4 (89.4-1228.4) | 131.5 (70.9-433.7) | 0.017 |
| uACR, mg/g Cr | 138.3 (47.8-476.5) | 221.5 (76.6-546.2) | 108.8 (33.9-302.3) | 0.006 |
| In-hospital outcomes | ||||
| ICU stay, d | 7.0 (4.0-12.0) | 7.0 (4.5-12.0) | 6.0 (3.0-12.0) | 0.296 |
| Acute dialysis, n (%) | 23 (15.4) | 23 (36.5) | 0 (0.0) | < 0.001 |
| In-hospital death, n (%) | 45 (30.2) | 45 (71.4) | 0 (0.0) | < 0.001 |
AKI progression is defined as worsening of AKI stage
a Serum creatinine level on the day of AKI diagnosis minus baseline serum creatinine level
Abbreviation: SCr serum creatinine, SCys-C serum cystatin C. u[TIMP-2]*[IGFBP7], urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7; uKIM-1, urinary kidney injury moleculer-1; uIL-18, urinary Interleukin-18; uACR, urinary albumin to creatinine ratio